2016
Potential Use of Flavopiridol in Treatment of Chronic Diseases
Srikumar T, Padmanabhan J. Potential Use of Flavopiridol in Treatment of Chronic Diseases. Advances In Experimental Medicine And Biology 2016, 929: 209-228. PMID: 27771926, DOI: 10.1007/978-3-319-41342-6_9.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnti-Inflammatory AgentsAntineoplastic Agents, PhytogenicAntiviral AgentsApoptosisCardiovascular AgentsCell Cycle CheckpointsCell ProliferationChronic DiseaseDisease Models, AnimalDrug DiscoveryFlavonoidsHumansMolecular StructurePhytotherapyPiperidinesPlants, MedicinalSignal TransductionConceptsChronic diseasesElicit anti-inflammatory activityAberrant cell cycle activationNFκB-dependent signalingEffect of flavopiridolAnti-inflammatory activityArrests cell cycle progressionCell cycle activationInflammatory stimuliAnti-apoptotic genesAnti-proliferative activityCell cycle progressionDiseaseInhibits expressionCycle activationFlavopiridolCycle progressionCDK inhibitorsPotential useGrowth-arrested cellsRecent studiesRNA polymerase II activationTreatmentP-TEFb complexActivation
2010
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors
Dickson MA, Rathkopf DE, Carvajal RD, Grant S, Roberts JD, Reid JM, Ames MM, McGovern RM, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK. A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Investigational New Drugs 2010, 29: 1004-1012. PMID: 20461440, PMCID: PMC3545439, DOI: 10.1007/s10637-010-9447-x.Peer-Reviewed Original ResearchConceptsSerum levelsPhase I pharmacokinetic studyIntermittent high doseResults 34 patientsD1-3I pharmacokinetic studyCyclin-dependent kinase inhibitor flavopiridolKinase inhibitor flavopiridolStable diseaseOral doseOral dosingHigh doseCombination treatmentPatientsSolid tumorsCmaxOne weekDosePharmacokinetic studyVorinostatMTDFlavopiridolNeutropeniaChemotherapyLevels
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply